Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

T Kalincik; JWL Brown; N Robertson; M Willis; N Scolding; CM Rice; A Wilkins; O Pearson; T Ziemssen; M Hutchinson; C McGuigan; V Jokubaitis; T Spelman; D Horakova; E Havrdova; M Trojano; G Izquierdo; A Lugaresi; A Prat; M Girard; P Duquette; P Grammond; R Alroughani; E Pucci; P Sola; R Hupperts; J Lechner-Scott; M Terzi; V Van Pesch; C Rozsa; F Grand'Maison; C Boz; F Granella; M Slee; D Spitaleri; J Olascoaga; R Bergamaschi; F Verheul; S Vucic; P McCombe; S Hodgkinson; JL Sanchez-Menoyo; R Ampapa; M Simo; T Csepany; C Ramo; E Cristiano; M Barnett; H Butzkueven; A Coles

Journal article

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

T Kalincik, JWL Brown, N Robertson, M Willis, N Scolding, CM Rice, A Wilkins, O Pearson, T Ziemssen, M Hutchinson, C McGuigan, V Jokubaitis, T Spelman, D Horakova, E Havrdova, M Trojano, G Izquierdo, A Lugaresi, A Prat, M Girard Show all

Lancet Neurology | ELSEVIER SCIENCE INC | Published : 2017

DOI: 10.1016/S1474-4422(17)30007-8

Download PDF

Abstract

Background Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy relative to more potent immunotherapies is unknown. We compared the effectiveness of alemtuzumab with natalizumab, fingolimod, and interferon beta in patients with relapsing-remitting multiple sclerosis treated for up to 5 years. Methods In this international cohort study, we used data from propensity-matched patients with relapsing-remitting multiple sclerosis from the MSBase and six other cohorts. Longitudinal clinical data were obtained from 71 MSBase centres in 21 countries and from six non-MSBase centres in t..

View full abstract